These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29699924)

  • 21. Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
    Chen X; Zhan P; Liu X; Cheng Z; Meng C; Shao S; Pannecouque C; De Clercq E; Liu X
    Bioorg Med Chem; 2012 Jun; 20(12):3856-64. PubMed ID: 22591854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Zhang J; Zhan P; Wu J; Li Z; Jiang Y; Ge W; Pannecouque C; De Clercq E; Liu X
    Bioorg Med Chem; 2011 Jul; 19(14):4366-76. PubMed ID: 21683601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
    Gawali R; Trivedi J; Bhansali S; Bhosale R; Sarkar D; Mitra D
    Eur J Med Chem; 2018 Sep; 157():310-319. PubMed ID: 30099253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
    Liu Z; Chen W; Zhan P; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2014 Nov; 87():52-62. PubMed ID: 25240095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
    Sakakibara N; Baba M; Okamoto M; Toyama M; Demizu Y; Misawa T; Kurihara M; Irie K; Kato Y; Maruyama T
    Antivir Chem Chemother; 2015 Feb; 24(1):3-18. PubMed ID: 26149262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
    Wang X; Zhang J; Huang Y; Wang R; Zhang L; Qiao K; Li L; Liu C; Ouyang Y; Xu W; Zhang Z; Zhang L; Shao Y; Jiang S; Ma L; Liu J
    J Med Chem; 2012 Mar; 55(5):2242-50. PubMed ID: 22283377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.
    Sweeney ZK; Acharya S; Briggs A; Dunn JP; Elworthy TR; Fretland J; Giannetti AM; Heilek G; Li Y; Kaiser AC; Martin M; Saito YD; Smith M; Suh JM; Swallow S; Wu J; Hang JQ; Zhou AS; Klumpp K
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4348-51. PubMed ID: 18625554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
    Jiang T; Kuhen KL; Wolff K; Yin H; Bieza K; Caldwell J; Bursulaya B; Tuntland T; Zhang K; Karanewsky D; He Y
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2109-12. PubMed ID: 16464578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors.
    Buckheit RW; Hartman TL; Watson KM; Kwon HS; Lee SH; Lee JW; Kang DW; Chung SG; Cho EH
    Antivir Chem Chemother; 2007; 18(5):259-75. PubMed ID: 18046959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
    Chen W; Zhan P; Rai D; De Clercq E; Pannecouque C; Balzarini J; Zhou Z; Liu H; Liu X
    Bioorg Med Chem; 2014 Mar; 22(6):1863-72. PubMed ID: 24581546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
    Côté B; Burch JD; Asante-Appiah E; Bayly C; Bédard L; Blouin M; Campeau LC; Cauchon E; Chan M; Chefson A; Coulombe N; Cromlish W; Debnath S; Deschênes D; Dupont-Gaudet K; Falgueyret JP; Forget R; Gagné S; Gauvreau D; Girardin M; Guiral S; Langlois E; Li CS; Nguyen N; Papp R; Plamondon S; Roy A; Roy S; Seliniotakis R; St-Onge M; Ouellet S; Tawa P; Truchon JF; Vacca J; Wrona M; Yan Y; Ducharme Y
    Bioorg Med Chem Lett; 2014 Feb; 24(3):917-22. PubMed ID: 24412110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Cesarini S; Spallarossa A; Ranise A; Schenone S; Bruno O; La Colla P; Casula L; Collu G; Sanna G; Loddo R
    Bioorg Med Chem; 2008 Jun; 16(12):6353-63. PubMed ID: 18502646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
    Li W; Li X; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2015 Sep; 102():167-79. PubMed ID: 26276432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase.
    Kodama E; Orita M; Masuda N; Yamomoto O; Fujii M; Ohgami T; Kageyama S; Ohta M; Hatta T; Inoue H; Suzuki H; Sudo K; Shimizu Y; Matsuoka M
    Antivir Chem Chemother; 2008; 19(3):133-41. PubMed ID: 19024630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Chen X; Li Y; Ding S; Balzarini J; Pannecouque C; De Clercq E; Liu H; Liu X
    ChemMedChem; 2013 Jul; 8(7):1117-26. PubMed ID: 23650275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
    Jiang T; Kuhen KL; Wolff K; Yin H; Bieza K; Caldwell J; Bursulaya B; Wu TY; He Y
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2105-8. PubMed ID: 16480865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
    Huang B; Li C; Chen W; Liu T; Yu M; Fu L; Sun Y; Liu H; De Clercq E; Pannecouque C; Balzarini J; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 92():754-65. PubMed ID: 25626145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
    Chimirri A; Grasso S; Monforte P; Rao A; Zappalà M; Monforte AM; Pannecouque C; Witvrouw M; Balzarini J; De Clercq E
    Antivir Chem Chemother; 1999 Jul; 10(4):211-7. PubMed ID: 10480739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivatives.
    Sakakibara N; Balboni G; Congiu C; Onnis V; Demizu Y; Misawa T; Kurihara M; Kato Y; Maruyama T; Toyama M; Okamoto M; Baba M
    Antivir Chem Chemother; 2015 Apr; 24(2):62-71. PubMed ID: 26514833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.